

Judith Derdelinckx

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7611367/publications.pdf>

Version: 2024-02-01

9
papers

134
citations

1478505

6
h-index

1720034

7
g-index

9
all docs

9
docs citations

9
times ranked

205
citing authors

#	ARTICLE	IF	CITATIONS
1	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. <i>BMJ Open</i> , 2019, 9, e030309.	1.9	63
2	Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. <i>Journal of Neuroinflammation</i> , 2019, 16, 167.	7.2	20
3	Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future. <i>Frontiers in Immunology</i> , 2021, 12, 624685.	4.8	15
4	GMP-Grade mRNA Electroporation of Dendritic Cells for Clinical Use. <i>Methods in Molecular Biology</i> , 2016, 1428, 139-150.	0.9	12
5	Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier In Vitro via the Introduction of De Novo CCR5 Chemokine Receptor 5 Expression Using Messenger RNA Electroporation. <i>Frontiers in Immunology</i> , 2018, 8, 1964.	4.8	8
6	Neuromyelitis Optica Spectrum Disorders in Africa. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	8
7	Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7536.	4.1	6
8	Towards a dendritic cell-based vaccine for the treatment of multiple sclerosis (MS): interim safety data of the first dose cohort of the MS-tolDC phase I clinical trial. <i>Frontiers in Neuroscience</i> , 0, 12, .	2.8	2
9	HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients. <i>Cells</i> , 2020, 9, 2703.	4.1	0